Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSC...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karan Seegobin, Umair Majeed, Nathaniel Wiest, Rami Manochakian, Yanyan Lou, Yujie Zhao
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
RET
Accès en ligne:https://doaj.org/article/9e3739d66fd3419fb78b4fe693d766c2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!